Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited has issued 6,856,460 new ordinary fully paid shares following the exercise or conversion of previously unquoted options or other convertible securities, with an effective issue date of January 9, 2026. The move increases the company’s share capital base and may modestly dilute existing shareholders, while signalling the crystallisation of value from earlier equity-based incentives or financing instruments as Mesoblast continues to fund and advance its therapeutic pipeline.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited, listed on the ASX under the code MSB, operates in the biotechnology and life sciences sector, focusing on the development and commercialisation of cellular medicines. The company’s activities centre on advanced therapies derived from mesenchymal lineage cells, targeting serious inflammatory and cardiovascular conditions for global markets.
Average Trading Volume: 4,197,680
Technical Sentiment Signal: Buy
Current Market Cap: A$3.94B
See more data about MSB stock on TipRanks’ Stock Analysis page.